Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease.
PE: The phase Ib trial demonstrated improvements in histology, symptoms, biomarkers, and nutrient absorption. Which of these findings do you consider most critical for advancing IMU-856 to later-stage trials?
Vitt: IMU-856 is quite unique for GI indications, including celiac disease because it is not immunosuppressive, but it’s able to establish the proper epithelial layer in the gut wall. Therefore, the histologic protection, which even achieves statistical significance by the very small number of patients involved here. The key endpoint is protecting the gut from histologic distraction. It’s also important for the development.
The second important endpoint is the functional improvement. I think this is something new and so far, not seen with other drugs or concepts, because if you restore the proper layer of cells there, then you also have more viable cells.
These cells are actively transporting nutrients from the gut wall into the body. For example, one of the functional endpoints was vitamin B12 uptake. We could see that in the patients during the four weeks of treatment that despite receiving gluten and the gluten challenge, there was an improvement in the dose dependent fashion, which we think speaks for the speed and the quality of an onset of action for the driver.
Full Interview Summary: The Phase Ib trial of IMU-856 demonstrated improvements across multiple endpoints, including histology, symptoms, biomarkers, and nutrient absorption. Among these, the most critical finding for advancing the drug to later-stage trials is its ability to restore the gut’s epithelial layer without immunosuppression. The drug achieved statistically significant histologic protection, even with a small patient sample, indicating its potential to preserve gut integrity. Additionally, functional improvements, such as increased vitamin B12 uptake despite gluten exposure, highlight its unique mode of action and rapid onset of efficacy.
IMU-856 offers a promising solution for celiac disease patients, particularly those at risk of symptom flare-ups due to cross-contamination with small amounts of gluten. By strengthening the gut barrier, the drug could benefit patients with active and severe disease, who often struggle with inadvertent gluten exposure.
Regarding safety and tolerability, the trial found IMU-856 to be well tolerated with no dose-dependent adverse events or maximum tolerated dose concerns. Chronic toxicology studies have also confirmed its potential for long-term use across various gastrointestinal disorders. The favorable safety profile allows for flexible dosing strategies, with the 160 mg dose already showing strong efficacy. Future studies may explore slight adjustments in dosage to optimize treatment.
With ongoing Phase III programs in neuroinflammation and multiple sclerosis, Immunic aims to establish itself at the forefront of both gastrointestinal and neuroinflammatory diseases. Collaborations and strategic partnerships will likely play a key role in expanding the drug’s applications.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Undertreated but High-Risk: The Hidden Health Crisis Facing 50+ Americans
May 15th 2025Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why many high-risk Americans aged 50+ remain undertreated for cardiovascular disease, citing insurance gaps, risk misperceptions, and complex guidelines.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Novo Nordisk’s Sogroya Demonstrates Efficacy in Children with Growth Disorders
May 14th 2025Results from the Phase III REAL8 basket study found that once-weekly Sogroya was effective in children with growth disorders, including those born small for gestational age, with Noonan syndrome, or idiopathic short stature.